BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-fda-503a-peptide-compounding-advisory-july-2026@catalyst-calendar.local
DTSTAMP:20260720T200612Z
DTSTART:20260723T130000Z
DTEND:20260723T133000Z
SUMMARY:FDA药房复方咨询委员会审议多种肽类503A Bulks List窗口
DESCRIPTION:FDA药房复方咨询委员会将在2026年7月23-24日讨论BPC-157、KPV、TB-500、MOTs-C、Semax、Epitalon等肽类复方物质，可能影响美国复方药房、肽类疗法和监管边界。\\nImpact score: 57\\nExpected: 咨询委员会讨论可能改变肽类复方供应、线上处方和未获批肽类产品监管预期。\\nAffected: XBI(etf\, mixed\, score 66)\; LLY(peer\, mixed\, score 62)\; NVO(peer\, mixed\, score 62)\; HIMS(theme\, unknown\, score 48)\; IBB(theme\, mixed\, score 40)\; ELV(peer\, mixed\, score 36)\\nSources: FDA advisory committee calendar: https://www.fda.gov/advisory-committees/advisory-committee-calendar\\nFDA Pharmacy Compounding Advisory Committee: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026\\nFederal Register notice: https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-fda-503a-peptide-compounding-advisory-july-2026
CATEGORIES:policy\,MACRO\,FDA\,compounding\,peptides\,GLP-1\,advisory committee\,regulation\,AdCom\,503A
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: FDA药房复方咨询委员会审议多种肽类503A Bulks List窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: FDA药房复方咨询委员会审议多种肽类503A Bulks List窗口
END:VALARM
END:VEVENT
END:VCALENDAR